Skip to main content

Questions About Treating Patients Using a CDK4/6 Inhibitor

Conference Correspondent 

Dr Matthew Goetz addresses common questions that arise when patients with HER+ metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.

Related Items